• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A Systematic Review of Clinical Features and Treatment Outcomes of Xanthoma Disseminatum.播散性黄色瘤的临床特征和治疗结果的系统评价
J Cutan Med Surg. 2024 Nov-Dec;28(6):572-576. doi: 10.1177/12034754241274356. Epub 2024 Aug 27.
2
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
3
Challenges in the Treatment of Xanthoma Disseminatum: Improvement in Disfiguring Facial Lesions with Cladribine and Brief Updated Literature Review.播散性黄瘤治疗中的挑战:克拉屈滨改善面部毁容性病变及文献简要更新综述
Clin Cosmet Investig Dermatol. 2025 Jun 30;18:1639-1644. doi: 10.2147/CCID.S528561. eCollection 2025.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
5
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块型银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
9
Interventions for infantile haemangiomas of the skin.皮肤婴儿血管瘤的干预措施。
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD006545. doi: 10.1002/14651858.CD006545.pub3.
10
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis.成人伴或不伴有广场恐惧症的惊恐障碍的心理治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2016 Apr 13;4(4):CD011004. doi: 10.1002/14651858.CD011004.pub2.

引用本文的文献

1
Challenges in the Treatment of Xanthoma Disseminatum: Improvement in Disfiguring Facial Lesions with Cladribine and Brief Updated Literature Review.播散性黄瘤治疗中的挑战:克拉屈滨改善面部毁容性病变及文献简要更新综述
Clin Cosmet Investig Dermatol. 2025 Jun 30;18:1639-1644. doi: 10.2147/CCID.S528561. eCollection 2025.

本文引用的文献

1
Clinical and pathological evaluation of cladribine treatment response in a case series of patients with xanthoma disseminatum.弥漫性黄色瘤病患者病例系列中克拉屈滨治疗反应的临床和病理评估。
Eur J Dermatol. 2023 Jun 1;33(3):270-279. doi: 10.1684/ejd.2023.4502.
2
Diabetes Insipidus: Pathogenesis, Diagnosis, and Clinical Management.尿崩症:发病机制、诊断及临床管理
Cureus. 2021 Feb 23;13(2):e13523. doi: 10.7759/cureus.13523.
3
Xanthoma disseminatum with extensive respiratory involvement effectively treated with cladribine: A case report.用克拉屈滨有效治疗广泛累及呼吸系统的播散性黄瘤:一例报告
Avicenna J Med. 2019 Apr 1;10(2):83-88. doi: 10.4103/ajm.ajm_177_19. eCollection 2020 Apr-Jun.
4
Xanthoma disseminatum with neurological involvement and optic atrophy: improvement with cladribine.播散性黄瘤伴神经受累及视神经萎缩:克拉屈滨治疗有效
BMJ Case Rep. 2019 May 21;12(5):e228464. doi: 10.1136/bcr-2018-228464.
5
Xanthoma disseminatum.播散性黄瘤
Lancet. 2018 Jan 20;391(10117):251. doi: 10.1016/S0140-6736(17)31934-7. Epub 2017 Oct 12.
6
Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.关于抗PCSK9单克隆抗体在高胆固醇血症患者中已发表的3期数据的系统评价。
Br J Clin Pharmacol. 2016 Dec;82(6):1412-1443. doi: 10.1111/bcp.13066. Epub 2016 Oct 4.
7
A case of xanthoma disseminatum with spontaneous resolution over 10 years: review of the literature on long-term follow-up.播散性黄色瘤病 10 年自发消退 1 例:长期随访文献复习。
Dermatology. 2011;222(3):236-43. doi: 10.1159/000328137. Epub 2011 May 26.
8
Xanthoma disseminatum.
Int J Dermatol. 2002 Dec;41(12):911-3. doi: 10.1046/j.1365-4362.2002.01680_1.x.
9
The various clinical patterns of xanthoma disseminatum. Considerations on seven cases and review of the literature.播散性黄瘤的各种临床模式。七例病例分析及文献综述
Dermatology. 1995;190(1):19-24. doi: 10.1159/000246628.

播散性黄色瘤的临床特征和治疗结果的系统评价

A Systematic Review of Clinical Features and Treatment Outcomes of Xanthoma Disseminatum.

机构信息

Department of Medicine, Université de Montréal, Montréal, QC, Canada.

Department of Medicine, McGill University, Montréal, QC, Canada.

出版信息

J Cutan Med Surg. 2024 Nov-Dec;28(6):572-576. doi: 10.1177/12034754241274356. Epub 2024 Aug 27.

DOI:10.1177/12034754241274356
PMID:39192594
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11585195/
Abstract

Xanthoma disseminatum (XD) is a rare normolipidemic mucocutaneous xanthomatosis within the spectrum of cutaneous non-Langerhans histiocytosis. Managing XD poses substantial challenges, with limited available data. This study aims to comprehensively evaluate existing literature on clinical features of XD and treatment outcomes. A systematic search of MEDLINE, Embase, and PubMed was performed, using "xanthoma disseminatum" and "Montgomery syndrome" as search terms, without restrictions. Screening was performed in duplicate by 2 reviewers. One hundred fifty-one studies met the inclusion criteria, yielding 166 cases of XD (106 females, 60 males), mean age at diagnosis 35.3 years (range: 9 months-87 years). XD typically presented as yellow-to-brown coalescing papules/plaques and nodules. Distribution affects mainly the face (n = 116/166), flexures (n = 45/166), trunk (n = 65/166), and genitalia/inguinal areas (n = 63/166). Most cases (99.4%; n = 165/166) exhibited extracutaneous manifestations, including the pituitary gland and the oropharynx. Treatment options rendered low complete response rates (CRRs). Treatments with reported outcomes included surgical resection (n = 17/99), systemic steroids (n = 40/99), immunosuppressants/immunomodulators (n = 73/99), energy-based devices (n = 7/99), lipid-lowering agents (n = 24/99), cryotherapy (n = 6/99), lasers (n = 10/99), topical steroids (n = 6/99), oral retinoids (n = 2/99), and radiotherapy (n = 5/99), with CCRs of 23.5% (n = 4/17), 5.0% (n = 2/40), 9.6% (n = 7/73), 14.3% (n = 1/7), 4.2% (n = 1/24), 16.7% (n = 1/6), 10.0% (n = 1/10), 0% (n = 0/6), 0% (n = 0/2), and 0% (n = 0/5), respectively. The most promising therapy is cladribine, with the highest CRR of 27.1% (n = 6/22) and the lowest no response rate (9.1%; n = 2/22) of all reported treatments. This review confirms the high prevalence of systemic manifestations in XD. Treatment options vary widely; thus, further research is needed to establish management strategies for this challenging condition.

摘要

播散性黄色瘤病 (XD) 是一种罕见的非朗格汉斯组织细胞谱系皮肤组织细胞增生症中的正常脂质皮肤黏膜黄瘤病。XD 的管理具有挑战性,因为现有数据有限。本研究旨在全面评估 XD 的临床特征和治疗结果的现有文献。通过使用“xanthoma disseminatum”和“Montgomery syndrome”作为检索词,对 MEDLINE、Embase 和 PubMed 进行了系统检索,没有任何限制。由 2 名审查员进行重复筛选。151 项研究符合纳入标准,共纳入 166 例 XD 患者(女性 106 例,男性 60 例),诊断时的平均年龄为 35.3 岁(范围:9 个月至 87 岁)。XD 通常表现为黄色至棕色融合的丘疹/斑块和结节。分布主要影响面部(n = 116/166)、弯曲处(n = 45/166)、躯干(n = 65/166)和生殖器/腹股沟区(n = 63/166)。大多数病例(99.4%;n = 165/166)存在皮肤外表现,包括垂体和口咽。治疗方法的完全缓解率(CRR)较低。具有报告结果的治疗方法包括手术切除(n = 17/99)、全身类固醇(n = 40/99)、免疫抑制剂/免疫调节剂(n = 73/99)、能量基设备(n = 7/99)、降脂药(n = 24/99)、冷冻疗法(n = 6/99)、激光(n = 10/99)、局部类固醇(n = 6/99)、口服类视黄醇(n = 2/99)和放射疗法(n = 5/99),CRR 分别为 23.5%(n = 4/17)、5.0%(n = 2/40)、9.6%(n = 7/73)、14.3%(n = 1/7)、4.2%(n = 1/24)、16.7%(n = 1/6)、10.0%(n = 1/10)、0%(n = 0/6)、0%(n = 0/2)和 0%(n = 0/5)。最有前途的治疗方法是克拉屈滨,其 CRR 最高为 27.1%(n = 6/22),所有报告的治疗方法中无反应率最低(9.1%;n = 2/22)。本综述证实 XD 存在很高的全身表现发生率。治疗方法多种多样;因此,需要进一步研究以建立这种具有挑战性疾病的管理策略。